Retaane® in Age-Related Macular Degeneration

Rudolf Foundation Clinic

Status and phase: Completed; Phase 3; Phase 2

Conditions: Age Related Macular Degeneration

Treatments: Drug: juxtascleral depot injection of Retaane

Study type: Interventional

Funder types: Other

Identifiers

NCT00569569

RFC012007

Details and patient eligibility

About

The treatment of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration currently presents a great challenge. With visual loss threatening, there are only very few therapeutic options.

While these patients are neither suitable for laser therapy nor for photodynamic therapy with Verteporfin, antiangiogenic drugs applied intravitreally are now available.

Some patients however reject this therapeutic option because of potential complications such as endophthalmitis and the frequency of necessary injections. 20 patients who rejected intravitreal therapy were treated with Anecortave acetate (Retaane®) which was applied as a juxtascleral depot injection.

Enrollment: 20 patients

Sex: All

Ages: 20 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• rejection of intravitreal injections
• presence of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration

Exclusion criteria

• conditions precluding judgement of the fundus

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

1

Experimental group

Description:

Patients treated with Retaane

Treatment:

Drug: juxtascleral depot injection of Retaane